جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

112 مُخرَج نتائج البحث عن «Pandemic»

مقالوصول مفتوح20262استشهاد· Semantic Scholar

Identification of Apixaban as a Potential Inhibitor of the SARS‐CoV‐2 Main Protease: A Multistage Computational Study

Journal of Chemistry · مجلد 2026 (1)

The SARS‐CoV‐2 main protease (M pro ) remains a critical therapeutic target for COVID‐19 intervention. In this study, we employed a comprehensive in silico repurposing strategy to identify FDA‐approved drugs with potential inhibitory activity against M pro . An initial molecular fingerprint screening of 3009 FDA‐approved compounds, based on similarity to the cocrystallized inhibitor X77, yielded 150 similar candidates. Subsequent structural similarity filtering reduced the list to 30 compounds, which were subjected to molecular docking. Apixaban demonstrated strong binding affinity and favorable interaction patterns within the M pro active site and was selected for further investigation. A 100‐ns molecular dynamics simulation comparing the apo and holo forms confirmed the structural stability of the M pro –apixaban complex. Apixaban remained stably positioned within the binding pocket, while reduced RMSF values in key active‐site residues indicated apixaban‐induced stabilization. Molecular mechanics–generalized Born surface area (MM‐GBSA) analysis estimated a binding free energy of −22.19 kcal/mol, with van der Waals interactions contributing predominantly to complex stability. Per‐residue decomposition highlighted significant contributions from Met165 and Gln189. Protein–ligand interaction fingerprinting (ProLIF) and protein–ligand interaction profiler (PLIP) analyses revealed persistent hydrogen bonds and hydrophobic contacts involving Asn142, Cys145, Gln189, Thr190, Gln192, and Arg188. Principal component analysis of trajectories (PCAT) demonstrated apixaban‐induced modulation of collective motions and partial closure of the binding pocket. Importantly, this study provides detailed atomistic insights into the potential interaction of apixaban with M pro . Together, these findings offer a plausible molecular rationale for its inhibitory activity and support further experimental and pharmacological evaluation of apixaban as a potential therapeutic candidate targeting SARS‐CoV‐2 M pro .

apixabanmain proteaseCOVID-19 pandemicdrug repurposing
مقالوصول مفتوح20261استشهاد· Semantic Scholar

Mesenchymal stem cell derived exosomes mitigate COVID-19 cytokine storm via Annexin A1 and TGF-β mediated MAPK pathway inhibition

Stem Cell Research & Therapy · مجلد 17 (1)

BACKGROUND: Severe COVID-19 is marked by a dysregulated inflammatory response, known as a cytokine storm, resulting in acute respiratory distress syndrome (ARDS) and multiple organ failure. Mesenchymal stem cell-derived exosomes (MSC-Exos) have demonstrated potential as immunomodulatory agents. This work investigates the possibility of MSC-Exos to mitigate excessive inflammation in COVID-19 by targeting the mitogen-activated protein kinase (MAPK) signalling pathway. METHODOLOGY: We integrated molecular docking analysis between TGF-β and Annexin A1 as exosomal proteins and key component proteins of the MAPK pathway (p38, ERK1/2, JNK1). The in-silico results were then validated in vivo using a Syrian hamster model of SARS-CoV-2 infection. Quantitative PCR (qPCR), western blotting, and histological examination were employed to evaluate the effects of MSC-Exos therapy on MAPK pathway activation, cytokine production, and lung tissue pathology. RESULTS: The in-silico study revealed extensive hydrogen bonding and hydrophobic interactions at the protein-protein interfaces between exosomal proteins and MAPK components. These interactions suggest that exosomal proteins may modulate MAPK signaling pathways. In vivo, MSC-Exos administration led to marked downregulation of pivotal genes in the MAPK signaling pathway (MEKK1, MEKK2, MEKK3), diminished phosphorylation of JNK1, p38, and ERK1/2, and lowered production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). Histopathological examination demonstrated ameliorated lung tissue structure, characterized by diminished alveolar wall thickness and decreased immune cell infiltration. CONCLUSION: MSC-Exos elicit immunomodulatory effects in SARS-CoV-2-Infected hamsters, partially by directly targeting and blocking the MAPK signaling pathway. These findings offer a compelling justification for the clinical assessment of MSC-Exos as a therapeutic approach to alleviate the cytokine storm and enhance outcomes in severe COVID-19 by targeting the ACE2-Independent pathway.

mesenchymal stem cell-derived exosomesCOVID-19 pandemiccytokine stormMAPK signaling
مقالوصول مغلق202519استشهاد· Semantic Scholar

Integrated in Silico and in Vitro Studies of Rutin's Potential against SARS-CoV-2 through the Inhibition of the RNA-dependent RNA Polymerase

Current Medicinal Chemistry · مجلد 32 (29) · 6353-6379

INTRODUCTION: In our quest to identify potent inhibitors against SARS-CoV-2, an extensive investigation was conducted for the binding and inhibitory efficacy of Rutin against nine SARS-CoV-2 proteins. METHODS: Structure Similarity, flexible alignment, Molecular Docking, molecular dynamics (MD) simulations and in vitro assays against the RdRp and SARS-CoV-2 have been conducted. RESULTS: The first step of our analysis involved a comprehensive examination of structural similarity among the co-crystallized ligands associated with those proteins. A substantial structural similarity was observed between Rutin and Remdesivir, the ligand of the SARS-CoV-2 RNAdependent RNA polymerase (RdRp). This similarity was validated through a flexible alignment study. Molecular docking studies, involving superimposition, revealed a notable resemblance in the mode of binding between Rutin and Remdesivir inside the active site of the RdRp. A 200 ns MD simulation confirmed that the RdRp-Rutin complex is more stable than the RdRp-Remdesivir complex. The MM-GBSA studies showed that Rutin had much more favorable binding energies, with a significantly lower value of -7.76 kcal/mol compared to Remdesivir's -2.15 kcal/mol. This indicates that the RdRp-Rutin binding is more robust and stable. PLIP and ProLIF studies helped clarify the 3D binding interactions and confirmed the stable binding seen in MD simulations. PCAT gave more insights into the dynamic behavior of the RdRp-Rutin complex. In vitro tests showed that Rutin has a strong inhibitory effect on RdRp with an IC50 of 60.09 nM, significantly outperforming Remdesivir, which has an IC50 of 24.56 μM. Remarkably, against SARS-CoV-2, Rutin showed a superior in vitro IC50 of 0.598 μg/ml compared to Remdesivir (12.47 μg/ml). The values of the selectivity index underscored the exceptional margin of safety of Rutin (SI: 1078) compared to Remdesivir (SI: 5.8). CONCLUSION: In conclusion, our comprehensive analysis indicates Rutin's promising potential as a potent SARS-CoV-2 RdRp inhibitor, providing a valuable insight for developing an effective COVID-19 treatment.

rutinSARS-CoV-2RNA-dependent RNA polymeraseRdRp inhibitors
مقالوصول مفتوح20255استشهاد· Semantic Scholar

Awareness and Knowledge of Pharmacists Regarding Herbal Medication and the Attitude and Demographics of their Consumers

Cureus · مجلد 17 (5) · e84250-e84250

INTRODUCTION: According to the World Health Organization (WHO), herbal medicines contribute to skills and practices used in cultures worldwide to manage physical and mental disorders. In Saudi Arabia during COVID-19, herbal medicine use increased due to the perceived safety of herbal medications, especially among pregnant women and individuals with health conditions. Objectives: The objective of this study was to determine the responsibilities and attitudes of community pharmacists toward herbal medicine use. METHODS: In this cross-sectional study, data were collected to obtain information on demographics, attitudes towards herbal medicines, safety knowledge, and the factors influencing communication. The selected sample included community pharmacists in Saudi Arabia. Results: Among the 387 pharmacist participants, the majority were male (n=313, 80.9%) and most acquired herbal medicine knowledge by Internet research (n=146, 37.7%) and from company information (n=139, 35.9%). There was a significant association between the perceived benefit of herbal medication by pharmacists with the non-agreement of using herbal medication from unknown sources (p < 0.05), and they observed that consumers are generally unaware of their possible adverse effects. The majority of participants claimed to be effectively and frequently communicating with their patients. Conclusion: Most participating pharmacists were male and primarily acquired herbal medicine knowledge through online resources and company information, with many recognizing both the benefits and potential risks of herbal products while actively communicating with patients. To improve public awareness and ensure safe herbal medication use, community pharmacists should receive further training and advocate for expanded research in this area.

herbal medicinecommunity pharmacistspharmacist knowledgepharmacist attitudes
مقالوصول مفتوح20255استشهاد· Semantic Scholar

Lyophilized MSC-EVs attenuates COVID-19 pathogenesis by regulating the JAK/STAT pathway

Stem Cell Research & Therapy · مجلد 16 (1) · 244-244

BACKGROUND: The JAK/STAT signaling pathway plays a crucial role in the release of interferons (IFNs) and the proinflammatory response during SARS-CoV-2 infection, contributing to the cytokine storm characteristic of severe COVID-19 cases. STAT3, a key protein in this pathway, has been implicated in promoting inflammation, making its inhibition a potential therapeutic strategy to mitigate disease severity. Mesenchymal Stem Cell-derived Extracellular Vesicles (MSC-EVs), enriched with immunomodulatory and antiviral miRNAs, offer a promising therapeutic approach by modulating gene expression and regulating inflammatory responses. This study investigates the ability of Lyophilized MSC-EVs to inhibit the JAK/STAT pathway, highlighting their potential application in COVID-19 management. METHODS: Male Syrian hamsters were used as an experimental model, housed under controlled laboratory conditions. SARS-CoV-2 (hCoV-19/Egypt/NRC-03/2020) was propagated in Vero E6 cells, and viral titers were determined using plaque assays. Hamsters were intranasally challenged with the virus and treated intraperitoneally with 0.5 mL of lyophilized human Wharton's jelly-derived MSC-extracellular vesicles (MSC-EVs). Histopathological evaluations were performed on lung tissues using H&E, Masson's trichrome, and immunohistochemical staining. Morphometric analyses were conducted to assess lung injury and fibrosis. Western blotting was employed to evaluate protein expression. All procedures adhered to ethical and biosafety guidelines. RESULTS: The administration of MSC-EVs significantly upregulated the expression levels of miRNA-146a, miRNA-124, miRNA-155, miRNA-29b, miRNA-7, miRNA-145 and miRNA-18a compared to their levels in the COVID-19 group, suggesting a targeted release of miRNA-cargo from the MSC-EVs into the lung tissue of the animals. MSC-EVs impaired the activation of the STAT3/STAT1 signaling pathway and reduced the cytokine storm and coagulopathy associated with COVID-19. CONCLUSIONS: These findings suggest that MSC-EVs have the potential to effectively mitigate the pathogenesis of COVID-19 by targeting the JAK/STAT signaling pathway. Further research is needed to fully understand the mechanisms underlying the therapeutic effects of MSC-EVs and their clinical application in combating the COVID-19 pandemic.

mesenchymal stem cell-derived extracellular vesiclesCOVID-19 pandemicSARS-CoV-2JAK/STAT signaling
مقالوصول مفتوح20254استشهاد· Semantic Scholar

Safety and efficacy of tocilizumab in COVID-19: A systematic evaluation of adverse effects and therapeutic outcomes

Journal of Infection and Public Health · مجلد 18 (10) · 102873-102873

BACKGROUND: While COVID-19 has transitioned from a pandemic to an endemic state, the management of its persistent complications continues to present substantial clinical challenges. Tocilizumab, an interleukin-6 receptor antagonist endorsed by the World Health Organization (WHO) for severe COVID-19 management, remains a critical therapeutic intervention. This systematic evaluation provides a comprehensive assessment of tocilizumab's safety and efficacy profile to inform clinical decision-making. METHODS: The study involved exhaustive search across multiple databases (PubMed, SCOPUS, WoS, BIOSIS) utilizing MeSH terms and Boolean operators to identify relevant studies. Methodological worthiness was rigorously evaluated utilizing the Risk of Bias 2 (RoB 2) tool. The statistical analysis of the findings incorporated one-way ANOVA, Mann-Whitney U tests, and Pearson's correlation coefficient (r) with 95 % confidence intervals to quantify adverse effects and therapeutic outcomes. RESULTS: The analysis of nine studies encompassing diverse demographic populations (ages ≥2 years, both sexes) established a clear safety profile for tocilizumab. The treatment demonstrated a statistically important association (P < 0.05) with mild adverse effects (nausea, diarrhea, headache, fatigue; r = 0.62, 95 % CI = 0.59-0.71) and moderate adverse effects (tremors, urinary difficulties, mood changes; r = 0.54, 95 % CI = 0.47-0.60). More concerning were the severe adverse effects, including hepatobiliary dysfunction and hypersensitivity reactions (r = 0.36, 95 % CI = 0.32-0.41), with rare but critical instances of acute liver failure (r = 0.18, 95 % CI = 0.15-0.22). Notably, despite this safety profile, tocilizumab exhibited significant therapeutic efficacy (P < 0.01) in ameliorating COVID-19 symptoms, particularly in cases complicated by cytokine storm syndrome. CONCLUSION: This study confirms tocilizumab's position as a valuable therapeutic agent for COVID-19 complications while highlighting the necessity for judicious patient selection and vigilant monitoring due to its potential for significant adverse effects. The findings underscore the importance of pre-treatment screening, adherence to contraindications, and ongoing pharmacovigilance to optimize risk-benefit ratios.

tocilizumabCOVID-19 pandemicIL-6 receptor inhibitordrug safety
مقالوصول مفتوح20252استشهاد· Semantic Scholar

In-silico screening of small compounds against Lassa fever haemorrhagic virus nucleoprotein

Scientific Reports · مجلد 15 (1) · 30558-30558

Lassa fever hemorrhagic virus (LFHV) outbreaks in Nigeria continue to increase. With the possibility of a potentially deadly pandemic and the absence of a vaccine, an effective candidate drug that presents with no adverse effects and better clinical outcomes is urgently needed; hence, the aim of the study. Retrieved ligands: 5-(Methylene) evodiamine, N-(2-Fluorobenzoyl) evodiamine, N-[[2-(3-chlorophenyl)-5-(trifluoromethyl) pyrazol-3-yl]methyl]-2-(1-methyl-2,3-dihydroindol-5-yl) propanamide (NCTPMMDP), lauric acid, and sofosbuvir, and the target protein, 3MX5, were prepared and utilised for docking, molecular dynamics simulation, ADMET profiling, and DFT using standard protocols. The docking score for lauric acid was the lowest, with a value of - 6.1, followed by the standard drug and co-crystal control drug with scores of - 9.1 and - 8.9 kcal/mol, respectively. On the other hand, the scores of the other ligands ranged from - 9.5 to - 12.3 kcal/mol. Molecular simulations revealed fluctuations in the RMSD and RMSF values; however, overall, the formed complexes were stable during most of the docking simulation runs. Principal component analysis (PCA) analysis showed that all the ligands, apart from lauric acid, showed better conformational changes within the backbone of the protein. ADMET profiling showed that the ligands were better oral drug candidates than sofosbuvir, as revealed by their better absorption values and absolute compliance with the Lipinski rule of five. The DFT result showed that, apart from lauric acid, all the test ligands possess small energy gaps indicative of high reactivity. Put together, these findings indicate that the test ligands possess anti-LHFV potential that merits further in vivo and in vitro evaluations.

nucleocapsid proteinantiviral drug discoverysmall-molecule ligandsmolecular docking
مقالوصول مفتوح2025

Stress, resilience, and social support among antenatal women in Jordan during the novel coronavirus pandemic: a cross-sectional study

Frontiers in Global Women s Health · مجلد 6 · 1573789-1573789

Background and aim The novel coronavirus pandemic has notably affected the psychological health of antenatal women, heightening their vulnerability to stress and raising questions about the impact of vaccination and fetal health outcomes. This study aims to examine the relationship between stress, resilience, and social support among antenatal women in Jordan during the novel coronavirus pandemic. Methodology Using a cross-sectional approach, 434 antenatal women were surveyed in November 2021. Participants were recruited through digital platforms, including social media (Facebook and Instagram). Eligibility criteria were participants should be at least 18 years old, pregnant, living in Jordan, and proficient in English. Results The mean perceived stress score among participants was 24.3 ± 4.4, with nearly half (49.3%) experiencing difficulty focusing, 48.9% finding daily tasks stressful, and 45.9% having trouble falling asleep. The mean social support score was 39.3 ± 9.1; the highest-rated support item was having someone available to drive them to a doctor. Pearson correlation revealed a significant positive association between resilience and social support ( r = 0.565, p < 0.01). Regression analysis identified later trimester, lack of insurance, and negative life changes during the pandemic as significant predictors of higher stress among pregnant women. These findings highlight that antenatal women in Jordan experienced considerable stress and moderate social support during the pandemic, and that social support is linked to higher resilience. Conclusion Antenatal women have experienced persistently high levels of anxiety and stress throughout the novel coronavirus pandemic. The mental health impacts are closely related to pandemic-driven factors such as isolation, interpersonal difficulties, and financial strain. Addressing these psychological outcomes and associated risk factors is essential before they worsen and impact both mothers and their unborn children.

perceived stressresiliencesocial supportpregnant women
مقالوصول مفتوح2025

Comparison of biomarkers and laboratory results in unaffected, moderate, and severe COVID-19 recovered patients

Future Science OA · مجلد 11 (1) · 2559553-2559553

AIM: To compare several laboratory results, including liver function, lipid metabolism (HDL), pulmonary function, and hematological parameters among COVID-19 recovered patients who were divided into two groups (asymptomatic/mild vs. moderate/severe). METHOD: The sample consisted of patients matched by age and gender. These patients were divided into two groups. The first group consisted of mild or mild cases, and the second group included moderate and severe cases, classified based on their need for oxygen. Blood samples were collected from all participants, and analyses for complete blood count, liver function markers, kidney function markers, and lipid profiles were conducted at the Health Center of Jordan University of Science and Technology and King Abdullah University laboratories. RESULTS: The analysis revealed Significant differences were noted in ALT (p = 0.002), DBC (p = 0.005), HDL (p = 0.035), Notably, the Forced Vital Capacity (FVC) showed a significant difference (F = 6.292, p = 0.012). The FEV1/FVC ratio was also highly significant (F = 45.054, p = 0.000). CONCLUSION: In this descriptive cohort study, the results indicating that specific biomarkers, such as elevated WBC and liver enzymes, are significantly associated with severe post-COVID outcomes. These findings highlight the systemic impact of the disease in severe cases, affecting multiple or one organ.

COVID-19 pandemicSARS-CoV-2disease severitybiomarkers
مقالوصول مفتوح2025

Knowledge and prevalence of loneliness and general psychiatric disorders during the coronavirus disease of 2019 (COVID-19) pandemic in Nigeria: A retrospective study

Journal of Nursing Advances in Clinical Sciences. · مجلد 2 (6) · 294-299

The coronavirus disease of 2019 (COVID-19) pandemic has significantly affected mental health worldwide, yet data on loneliness and psychiatric disorders in Nigeria remain limited. This study assessed the prevalence of loneliness and psychiatric disorders and examined associated sociodemographic factors among Nigerian adults during the pandemic. A retrospective online survey was conducted among 502 respondents between October 10 to October 25, 2022, using the UCLA Loneliness Scale and the General Health Questionnaire-12 (GHQ-12). Descriptive statistics and chi-square tests were applied to assess prevalence and associations; p-values <0.05 were considered significant. The prevalence of loneliness was 37.9%, while psychiatric morbidity (GHQ-12 score ≥3) was 53.9%. Loneliness was significantly associated with female gender (P=0.02), younger age (P=0.010), and unemployment (P=0.030). Psychiatric disorders were associated with female gender (P=0.040), low income (P=0.020), and pre-existing medical conditions (P=0.010). Loneliness and psychiatric disorders were common during the COVID-19 pandemic in Nigeria, particularly among women, young adults, and those with socioeconomic vulnerabilities. Targeted interventions and integration of mental health services into pandemic preparedness are essential to mitigate these impacts.

lonelinessmental illnessCOVID-19 pandemicmental health
مقالوصول مغلق2025

Angiotensin‐Converting Enzyme 2 (G8790A) Gene Polymorphism as a Risk Factor for COVID‐19 in Egyptian Children and Adolescents

Pediatric Pulmonology · مجلد 60 (1) · e27479-e27479

OBJECTIVE: Recently, angiotensin-converting enzyme 2 (ACE2) gene has emerged as a potential candidate gene for susceptibility to SARS-CoV-2 infection. We investigated whether ACE2 G8790A (rs2285666) polymorphism could be a genetic marker for susceptibility to COVID-19 and disease severity in Egyptian children and adolescents. METHODS: This was a prospective case-control study included 580 cases diagnosed with COVID-19, and 580 matched control children and adolescents. The ACE2 G8790A (rs2285666) polymorphism was genotyped using polymerase chain reaction (PCR) and ACE2 serum level was measured by ELISA. RESULTS: The ACE2 A/A genotype and A-allele were significantly more represented in cases with COVID-19 as compared to control group (44% vs. 30%; OR = 2.83; [95% CI: 1.27-2.63]; p = 0.006; for the A/A genotype) and (65% vs. 51%; OR = 1.9; [95% CI: 1.06-1.72]; p = 0.01; for the A-allele). The presence of ACE2 G/G genotype was an independent risk factor for severe disease (adjusted OR: 2.08; [95% CI: 1.57-6.78]; p = 0.003). CONCLUSION: The ACE2 G8790A (rs2285666) polymorphism may confer susceptibility to COVID-19 in Egyptian children and adolescents. The ACE2 G/G genotype and G-allele was associated with lower ACE2 serum levels and may constitute independent risk factors for disease severity.

COVID-19 pandemicSARS-CoV-2ACE2 geners2285666
مقالوصول مفتوح202412استشهاد· Semantic Scholar

Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach

Antiviral Therapy · مجلد 29 (6) · 13596535241305536-13596535241305536

Background The COVID-19 pandemic has created an urgent need for effective therapeutic agents. The SARS-CoV-2 Main Protease (M pro ) plays a crucial role in viral replication and immune evasion, making it a key target for drug development. While several studies have explored M pro inhibition, identifying FDA-approved drugs with potential efficacy remains a critical research focus. Purpose This study aims to identify FDA-approved drugs that could inhibit SARS-CoV-2 M pro . Using computational screening, we seek compounds that share structural similarities with a known co-crystallized ligand (PRD_002214) and exhibit strong binding affinity to the enzyme, providing viable candidates for COVID-19 treatment. Research Design A systematic in silico approach was used, screening 3009 FDA-approved drugs. The initial screening focused on structural similarity to PRD_002214 (PDB ID: 6LU7), followed by molecular docking studies to predict binding affinity. Promising compounds were further analyzed through molecular dynamics (MD) simulations to evaluate their stability and interactions with M pro over 100 ns. Study Sample Of the 3009 FDA-approved drugs screened, 74 were selected for initial evaluation. After refinement, 28 compounds underwent docking analysis, with eight showing strong binding potential to M pro . Analysis Molecular docking assessed the binding affinity and interaction of the selected compounds with M pro . MD simulations were conducted on the top compound, Atazanavir, to study its dynamic interactions. MM-GBSA, PLIP, and PCAT analyses were used to validate binding affinity and interactions. Results Eight compounds, including Carfilzomib, Atazanavir, Darunavir, and others, exhibited promising binding affinities. Among them, Atazanavir showed the highest binding strength and was selected for further MD simulation studies. These simulations revealed that Atazanavir forms stable interactions with M pro , demonstrating favorable binding and dynamic stability. The binding affinity was further confirmed through MM-GBSA, PLIP, and PCAT analyses, supporting Atazanavir's potential as an effective M pro inhibitor. Conclusions In silico results suggest that Atazanavir is a promising candidate for targeting SARS-CoV-2 M pro , with strong binding affinity and dynamic stability. These findings support its potential as a lead compound for further preclinical and clinical testing, though in vitro and in vivo validation are needed to confirm its therapeutic efficacy against COVID-19.

COVID-19 pandemicmain proteaseMpro inhibitorsFDA-approved drugs
مقالوصول مفتوح202410استشهاد· Semantic Scholar

Discovery of potential FDA-approved SARS-CoV-2 Papain-like protease inhibitors: A multi-phase in silico approach

Journal of Chemical Research · مجلد 48 (6)

Papain-like protease (PLpro) is a crucial enzyme for SARS-CoV-2 replication and immune evasion. Inhibiting PLpro could be a promising strategy to fight against COVID-19. This study aimed to identify potent inhibitors of PLpro among FDA-approved drugs using an in silico approach. The study also aimed to examine and confirm the binding of the selected compounds to the active pocket of PLpro using a multi-phased in silico approach, involving the screening of 3009 FDA-approved drugs to pinpoint the most similar compounds to, TTT, the co-crystallized ligand TTT of PLpro. The selected compounds were subjected to further analysis, including molecular docking, molecular dynamics simulations, MM-GPSA (molecular mechanics generalized Born surface area), and PLIP (Protein-Ligand Interaction Profiler) studies, to examine and confirm their binding to the active pocket of PLpro. Seven candidates (Vismodegib, Celecoxib, Ketoprofen, Indomethacin, Naphazoline, Valdecoxib, and Eslicarbazepine) showed promising in silico activities against the PLpro. The computational analysis confirmed the binding of Celecoxib to the active pocket of PLpro, suggesting its potential in the fight against COVID-19. This study identified seven FDA-approved drugs as potential inhibitors of PLpro, providing a feasible approach for drug repurposing against COVID-19. The results obtained from the in silico approach hold promise, but further in vitro and in vivo studies are warranted to validate the potential of these compounds.

SARS-CoV-2papain-like proteasePLpro inhibitorsCOVID-19 pandemic